The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
How biologics have changed clinical practice over conventional chemotherapies and currently available biosimilars in the US.
Pharmacists working collaboratively can make an impact, including for patients with more acute diseases.
Study: Liquid Biopsies a Possible Method for Improved Breast Cancer Detection, Monitoring Progression
Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.
Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.
Researchers Report Positive Preliminary Data, Favorable Safety Update for Pelareorep in Breast Cancer
The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.
Small cell lung cancer is highly aggressive and fast-growing, typically recurring and progressing rapidly despite the initial response to chemotherapy.
A highlighted session from the ASHP 54th Midyear Clinical Meeting, held December 8-12, 2019, in Las Vegas, Nevada.
New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.
DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.
New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.
Study: Genetic Testing Recommended for Some Postmenopausal Women with Breast Cancer, No Hereditary Risk Factors
Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.
A study published in Clinical Cancer Research has shown that using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC) can predict tumor sensitivity to 3 systematic cancer therapies by using artificial intelligence (AI).